Results 41 to 50 of about 2,929 (206)

Effect of Acid Suppressants on Non–Helicobacter pylori Helicobacters Within Parietal Cells

Frontiers in Pharmacology, 2022
We investigated the effect of increased pH induced by acid suppressants on the viability of non–Helicobacter pylori helicobacters (NHPHs) within parietal cell intracellular canaliculi and fundic glandular lumina by immunohistochemistry, electron ...
Masahiko Nakamura, Futa Murasato, Anders Øverby, Yosuke Kodama, Hirofumi Michimae, Kazuki Sasaki, Bram Flahou, Freddy Haesebrouck, Somay Y. Murayama, Shinichi Takahashi, Masayuki Uchida, Hidekazu Suzuki, Hidenori Matsui   +12 more
doaj   +1 more source

Cost-effectiveness Analysis Comparing Vonoprazanbased Triple Therapy with Proton Pump Inhibitorbased Therapy in the Treatment of Helicobacter pylori Infection in Thailand

Siriraj Medical Journal, 2021
Objective: Helicobacter pylori (H. pylori) infection is one of the leading causes of gastrointestinal diseases such as dyspepsia, peptic ulcers. Thailand has a 45.9% prevalence of the infection and an increasing rate of resistance to clarithromycin ...
Jadesada Lertsirimunkong, Wiwat Thavornwattanayong, Yosita Napuk, Watcharapong Ajcharoen, Vipavee Chaisitsanguan, Supasuta Wachiranukornkul   +5 more
doaj   +1 more source

Review ‐ Treatment of Helicobacter pylori Infection 2020 [PDF]

, 2020
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2019 to April 2020. The main themes that emerge involve studies assessing antibiotic resistance and there is also growing momentum behind the utility of ...
Furuta, Takahisa, Gisbert, P. Javier, O'Connor, Anthony, O'Morain, Colm   +3 more
core   +1 more source

Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial

BMC Gastroenterology, 2021
Background Vonoprazan is more potent and longer acting than traditional proton pump inhibitor. Although vonoprazan is expected to be superior to proton pump inhibitor, its efficacy in the treatment of gastric ulcers following endoscopic submucosal ...
Daisuke Kawai, Ryuta Takenaka, Mikako Ishiguro, Shotaro Okanoue, Tatsuhiro Gotoda, Yoshiyasu Kono, Koji Takemoto, Hirofumi Tsugeno, Shigeatsu Fujiki   +8 more
doaj   +1 more source

Vonoprazan pharmacokinetics and effects on gastric pH following administration to fed and fasted horses

Equine Veterinary Journal, EarlyView.
Abstract Background Current treatment options for equine gastric ulcer syndrome (EGUS), such as omeprazole—a proton pump inhibitor (PPI)—have notable limitations, including the need for administration on an empty stomach. Potassium‐competitive acid blockers (P‐CABs), such as vonoprazan, are a newer class of acid suppressants that offer several ...
Camilo J. Morales, Benjamin W. Sykes, Daniel S. McKemie, Philip H. Kass, Heather K. Knych   +4 more
wiley   +1 more source

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo

Frontiers in Pharmacology, 2020
BackgroundVonoprazan fumarate is a potassium-competitive acid blocker that was developed as a novel acid-suppressing drug for multiple indications. As a potential alternative to proton-pump inhibitors, the determination of the drug-drug interactions is ...
Yiran Wang, Changxiong Wang, Shuanghu Wang, Quan Zhou, Dapeng Dai, Jihua Shi, Xue Xu, Qingfeng Luo   +7 more
doaj   +1 more source

Rationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations ...
Somchai Leelakusolvong, Tju Siang Chua, Duc Trong Quach, Andrew Ming‐Liang Ong, Ari Fahrial Syam, Augusto Jose G. Galang, Wee Kooi Cheah, Hang Viet Dao, Jose D. Sollano, Kalwinder Singh Khaira, Phuripong Kijdamrongthum, Rahela Ambaras Khan, Sakkarin Chirapongsathorn, Yeong Yeh Lee   +13 more
wiley   +1 more source

Cross-Roads for Meta-Analysis and Network Meta-Analysis of H. pylori Therapy [PDF]

, 2021
Helicobacter pylori infections are responsible for tremendous morbidity and mortality worldwide, leading to efforts to eradicate the organism. However, the effectiveness of antimicrobial therapy has been undermined by the progressive development of ...
Graham, David Y, Hernaez, Ruben, Rokkas, Theodore   +2 more
core   +2 more sources

Intravenous Tolvaptan Sodium Phosphate Can Fail to Improve Fluid Overload Due to Heart Failure in Patients With Chronic Kidney Disease: A Case Report

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Tolvaptan is widely used as an adjunct oral diuretic to loop and thiazide diuretics for the management of fluid overload in patients with congestive heart failure. Recently, tolvaptan sodium phosphate (TSP), a water‐soluble prodrug of tolvaptan, was developed for intravenous administration and has demonstrated efficacy and safety in clinical ...
Takaya Uno, Ichiro Nakakura, Akari Ikeda, Atsuki Hosoda, Yutaro Mukai, Kaori Yamanishi, Naohiro Ohara, Kaori Imanishi, Yoshiko Une, Satoshi Yokoyama, Kouichi Hosomi   +10 more
wiley   +1 more source

The pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 5, Page 1153-1161, May 2026.
Abstract Objectives Vonoprazan, a potassium‐competitive acid blocker, provides more rapid, potent, and durable elevations in gastric pH than proton pump inhibitors in adults and may be a treatment option for adolescents and children with gastroesophageal reflux disease (GERD).
Darcy J. Mulford, David A. Gremse, Yu‐Ming Chang, Eckhard Leifke, Thomas Wagner, Axel Facius, Galen Witt   +6 more
wiley   +1 more source